Jiangsu Sihuan Bioengineering Co Ltd

Jiangsu Sihuan Bioengineering Co., Ltd. produces and sells biopharmaceutical products in China and internationally. Its products include Delusen and New Delusen, a human interleukin-2 for injection used as an immunomodulator for tumor biotherapy and for patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection for neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection for anemia caused by renal insufficiency. The company also engages in flower planting, forest and natural ecosystem management and protection, forest improvement, forestry product sales, Chinese herbal medicine planting, landscaping project construction, urban municipal greening management, scenic area management, municipal facilities management, earthwork construction, engineering management services, forest park management and design management, external contracting, project cost consulting services, and the sale of metal materials, agricultural and sideline products, and building and decoration materials. Founded in 1992, it is headquartered in Jiangyin, China.

000518.CS▼

Sihuan Bio's 2026 interim report shows net loss of 25.83 million yuan

Sihuan Bio has released its 2026 interim report, with net profit attributable to the parent company at a loss of 25.83 million yuan, an increase in loss of 15.73 million yuan compared with the same period last year. The company's total operating revenue was 111 million yuan, down 39.12 percent year on year, and net cash flow from operating activities was a negative 17.27 million yuan, down 134.43 percent year on year. The company's latest asset-liability ratio was 28.00 percent, gross margin was 20.57 percent, return on equity was negative 8.37 percent, and diluted earnings per share was negative 0.03 yuan.

000518.CS ▼

Jiemian·29dRead more →

000518.CS▲2

Sihuan Bio to Acquire 80% Stake in Changyuan Pharmaceutical for 160 Million Yuan

Sihuan Bio announced that the company plans to acquire an 80% stake in Jilin Changyuan Pharmaceutical for 160 million yuan in cash. The target company is mainly engaged in the production and sale of pharmaceuticals, with its core product being succinylated gelatin injection. The transaction is still in the planning stage, and there is uncertainty as to whether it will ultimately be completed.

000518.CS ▲

CLS·33dRead more →